Management of Parkinson disease.
Mandanas
L
L
D000328:Adult; D000367:Age Factors; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D003693:Delirium / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D000077152:Olanzapine; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine